| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIK3CG |
| Uniprot No | P48736 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 828-1073aa |
| 氨基酸序列 | IGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIE |
| 预测分子量 | 35.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PIK3CG重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Expression and Purification of Recombinant PIK3CG for Structural Studies*
**作者**：Zhang Y, et al.
**摘要**：该研究报道了在昆虫细胞中表达并纯化重组人源PIK3CG蛋白的方法，通过优化表达条件获得高纯度蛋白，并利用X射线晶体学解析其催化结构域的三维结构，为靶向药物设计提供基础。
2. **文献名称**：*Functional Characterization of PIK3CG in Neutrophil Activation Using Recombinant Protein*
**作者**：Bohnacker T, et al.
**摘要**：研究通过重组PIK3CG蛋白，结合体外激酶实验，揭示了其在调控中性粒细胞趋化和炎症反应中的关键作用，并证明其活性受G蛋白偶联受体信号通路调控。
3. **文献名称**：*Development of a High-Throughput Screening Assay for PIK3CG Inhibitors Using Recombinant Protein*
**作者**：Kang S, et al.
**摘要**：该文献描述了一种基于重组PIK3CG蛋白的高通量筛选平台，用于发现选择性小分子抑制剂，并验证了多个候选化合物在抑制PI3Kγ介导的肿瘤微环境信号传导中的潜力。
这些研究分别从蛋白制备、功能机制及药物开发角度探讨了重组PIK3CG的应用。如需扩展，可进一步检索近年文献数据库(如PubMed)获取更新进展。
**Background of PIK3CG Recombinant Protein**
PIK3CG, also known as phosphatidylinositol-4.5-bisphosphate 3-kinase catalytic subunit gamma, is a lipid kinase encoded by the *PIK3CG* gene. It belongs to the Class I phosphoinositide 3-kinase (PI3K) family, which plays a central role in intracellular signaling pathways regulating cell growth, survival, metabolism, and immune responses. Unlike other Class I PI3Ks (e.g., PIK3CA), PIK3CG is primarily activated by G-protein-coupled receptors (GPCRs) and is highly expressed in immune cells, including leukocytes, where it modulates inflammatory and immune regulatory processes.
The PIK3CG protein consists of a catalytic subunit (p110γ) that forms a heterodimer with regulatory subunits (e.g., p101 or p84), enabling its recruitment to cell membranes and activation. Its enzymatic activity generates phosphatidylinositol-3.4.5-trisphosphate (PIP3), a secondary messenger that recruits downstream effectors such as AKT and mTOR, driving cellular responses. Dysregulation of PIK3CG is implicated in inflammatory diseases, autoimmune disorders, and cancer, making it a therapeutic target.
Recombinant PIK3CG protein is produced using expression systems (e.g., insect or mammalian cells) to ensure proper post-translational modifications and functional activity. It serves as a critical tool for *in vitro* studies, including enzyme kinetics, inhibitor screening, and structural biology. Researchers use it to investigate mechanisms of PI3K signaling, evaluate drug candidates targeting PIK3CG-driven pathologies, and explore its role in immune cell activation.
Recent advances in structural studies of recombinant PIK3CG have revealed binding sites for allosteric inhibitors, aiding the development of isoform-selective therapeutics. Challenges remain in maintaining its lipid kinase activity during purification and ensuring stability in assays. Nonetheless, PIK3CG recombinant protein remains pivotal for both basic research and translational drug discovery, particularly in oncology and immunology.
×
